• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Eur J Endocrinol . THYROTOXICOSIS IN PATIENTS WITH COVID-19: THE THYRCOV STUDY

tetano

Editor, Senior Moderator
Eur J Endocrinol


. 2020 Jul 1;EJE-20-0335.R2.
doi: 10.1530/EJE-20-0335. Online ahead of print.
THYROTOXICOSIS IN PATIENTS WITH COVID-19: THE THYRCOV STUDY


Andrea Lania[SUP] 1 [/SUP], Maria Teresa Sandri[SUP] 2 [/SUP], Miriam Cellini[SUP] 3 [/SUP], Marco Mirani[SUP] 4 [/SUP], Elisabetta Lavezzi[SUP] 5 [/SUP], Gherardo Mazziotti[SUP] 6 [/SUP]



Affiliations

Abstract

Objective: This study assessed thyroid function in patients affected by the coronavirus disease-19 (COVID-19), based on the hypothesis that the cytokine storm associated with COVID-19 may influence thyroid function and/or the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may directly act on thyroid cells, such as previously demonstrated for SARS-CoV-1 infection.
Design and methods: This single-center study was retrospective and consisted in evaluating thyroid function tests and serum interleukin-6 (IL-6) values in 287 consecutive patients (193 males, mean age 64.3?14.0 years, range: 27-92), hospitalized for COVID-19 in non-intensive care units.
Results: Fifty-eight patients (20.2%) were found with thyrotoxicosis (overt in 31 cases), 15 (5.2%) with hypothyroidism (overt in only 2 cases), 214 (74.6%) with normal thyroid function. Serum thyrotropin (TSH) values were inversely correlated with age of patients (rho -0.27; p<0.001) and IL-6 (rho -0.41; p<0.001). In the multivariate logistic regression analysis, thyrotoxicosis resulted to be significantly associated with higher IL-6 (odds ratio 3.25, 95% confidence interval 1.97-5.36; p<0.001), whereas the association with age of patients was lost (p=0.09).
Conclusions: This study provides a first evidence that COVID-19 may be associated with high risk of thyrotoxicosis in relationship with systemic immune activation induced by the SARS-CoV-2 infection.
 
Back
Top Bottom